摘要
膀胱癌是泌尿系统常见的肿瘤之一，随着人们生活节奏的加快和生活方式的转变，膀胱癌的发病率呈逐年上升趋势，以往的治疗方式主要为开放式手术或经尿道膀胱肿瘤电切术，这些治疗方式不但创伤较大，而且还无法克服膀胱癌易复发的特性。进入21世纪以来随着分子生物学技术的飞速发展，对膀胱癌的诊疗已进入分子时代，Survivin基因的发现、热休克蛋白分子在肿瘤免疫学中的新认识及RNA干扰技术的进步，为膀胱肿瘤的早期诊断、治疗开辟了全新的领域。本文就Survivin基因促进肿瘤形成的原理、其反义RNA的功效，以及HSP70分子在肿瘤免疫方面的作用展开论述，旨在探讨Survivin反义RNA与HSP70构建的双基因表达载体治疗膀胱癌的可行性。
Carcinoma of urinary bladder is one of the most common tumor. As life rhythm speeding up and lifes- tyle changing, bladder cancer incident increases year after year. Previous major treatment methods for the disease are open surgery and TURBT,but these therapies can not overcome the characteristics of its recurrence. Since the 21st century along with the rapid development of molecular biology technology, the discovery of Survivin gene, new knowl- edge about HSP molecules in tumor immunology and the progress of the technique called RNA interference, open up a whole new field for early diagnosis and treatment of bladder carcinoma. Discussing the role of Survivin gene in the development of tumor, survivin antisense RNA＇ s efficacy and the role of HSP70 in the cancer immunity, the review aims at exploring the possibility of the double gene expression vector constructed by Survivin antisense RNA gene and HSP70 gene for bladder carcinoma therapy.
出处
《国际外科学杂志》
2012年第5期349-353,共5页
International Journal of Surgery
